Article

Meningococcal Sepsis Complicating Eculizumab Treatment Despite Prior Vaccination

Renal Transplant Unit, Department of Nephrology, Division of Internal Medicine, Academic Medical Center, University of Amsterdam, the Netherlands.
American Journal of Transplantation (Impact Factor: 5.68). 01/2013; 13(3). DOI: 10.1111/ajt.12032
Source: PubMed
Download full-text

Full-text

Available from: Frederike Jose Bemelman, Sep 19, 2014
  • Source
    • "e l s e v i e r . c o m / l o c a t e / y c l i m clinical practice, mainly due to the following concerns: a certain, though small, risk of meningococcal infection and sepsis [24] [25], possible immunological complications in the long term, including development of neutralizing antibodies, and the extremely high cost of this treatment. Although approval of eculizumab signified new hope for the aHUS patients, available reports describing pharmacokinetic and pharmacodynamics of this drug remain limited. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Complement C5 inhibitor eculizumab treatment in atypical hemolytic uremic syndrome is effective, but associated with high costs. Complement inhibition monitoring in these patients has not been standardized. In this study we evaluated novel functional assays for application in routine follow-up. We documented that the Wieslab® complement screen assay showed a sensitivity of 1-2% of C5 activity by adding purified C5 or normal human serum to a C5 deficient serum. All the patient samples obtained during the treatment course, were completely blocked for terminal complement pathway activity for up to four weeks after the eculizumab infusion. Levels of complexes between eculizumab and C5 were inversely correlated to the complement activity (p=0.01). Moreover, titrating serum from eculizumab-treated patients into normal serum revealed that eculizumab was present in excess up to four weeks after infusion. Thus, we demonstrate sensitive, reliable and easy-performed assays which can be used to design individual eculizumab dosage regimens.
    Full-text · Article · Sep 2015 · Clinical Immunology
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Immunosuppressive treatments increase the life-long risk of solid organ transplant (SOT) recipients for severe infections, some of which are vaccine-preventable. In this review of the literature published during the last 15 months, we critically summarize vaccine-oriented articles in SOT candidates or recipients. Because of previously reported differences, vaccine-specific studies are needed for each type of SOT recipients. Thanks to new data gathered during the H1N1/2009 influenza pandemic, recent research mainly focused on influenza vaccination, especially in kidney transplantation. Lung transplantation, mycophenolate treatment, increasing age and end-stage organ failure were frequently identified as risk factors for nonresponse to immunization in general. New evidence concerning the safety of immunizing SOT recipients with live-attenuated vaccines is obtained. During this last year, more encouraging data have been published regarding safety and immunogenicity of vaccination in SOT recipients. New inventive strategies should be studied to overcome missed opportunities for vaccinating SOT candidates and recipients, and to promote the most effective vaccination schedule and follow-up.
    Full-text · Article · Jul 2013 · Current opinion in organ transplantation
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Atypical hemolytic and uremic syndrome (aHUS) is associated with a high rate of recurrence and poor outcomes after kidney transplantation. Fortunately, recent advances in the understanding of the pathogenesis of aHUS have permitted an individualized risk assessment of post-transplant recurrence. Acquired or inherited dysregulation of the alternative complement pathway, thought to be the driving force of the disease, is identified in most aHUS patients. Notably, depending on the mutations involved, the risk of recurrence greatly varies, highlighting the importance of undertaking etiological investigations prior to kidney transplantation. In those with moderate to high risk of recurrence, the use of a prophylactic therapy, consisting in either plasmapheresis or eculizumab therapies, represents a major stride forward in the prevention of aHUS recurrence after kidney transplantation. In those who experience aHUS recurrence, a growing number of observations suggest that eculizumab therapy outperforms curative plasma therapy. The optimal duration of both prophylactic and curative therapies remains an important, yet unaddressed, issue. In this respect, the kidney transplant recipients, continuously exposed to endothelial-insulting factors, referred here as to triggers, might have a sustained high risk of recurrence. A global therapeutic approach should thus attempt to reduce exposure to these triggers.
    Full-text · Article · Aug 2013 · Transplantation reviews (Orlando, Fla.)
Show more